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Background: Increased ferritin concentrations are associated with metabolic syndrome (MetS). The association
between ferritin as well as hemoglobin level and individual MetS components is unclear. Erythropoietin levels in
subjects with MetS have not been determined previously. The aim of this study was to compare serum
erythropoietin, ferritin, haptoglobin, hemoglobin, and transferrin receptor (sTFR) levels between subjects with and
without MetS and subjects with individual MetS components.
Methods: A population based cross-sectional study of 766 Caucasian, middle-aged subjects (341 men and 425
women) from five age groups born in Pieksämäki, Finland who were invited to a health check-up in 2004 with no
exclusion criteria. Laboratory analyzes of blood samples collected in 2004 were done during year 2010. MetS was
defined by National Cholesterol Education Program criteria.
Results: 159 (53%) men and 170 (40%) women of study population met MetS criteria. Hemoglobin and ferritin
levels as well as erythropoietin and haptoglobin levels were higher in subjects with MetS (p < 0.001, p = 0.018). sTFR
level did not differ significantly between subjects with or without MetS. Hemoglobin level was significantly higher
in subjects with any of the MetS components (p < 0.001, p = 0.002). Ferritin level was significantly higher in subjects
with abdominal obesity or high TG or elevated glucose or low high density cholesterol component (p < 0.001,
p = 0.002, p = 0.02). Erythropoietin level was significantly higher in subjects with abdominal obesity component
(p = 0.015) but did not differ significantly between subjects with or without other MetS components. Haptoglobin
level was significantly higher in subjects with blood pressure or elevated glucose component o MetS (p = 0.028,
p = 0.025).
Conclusion: Subjects with MetS have elevated hemoglobin, ferritin, erythropoietin and haptoglobin concentrations.
Higher hemoglobin levels are related to all components of MetS. Higher ferritin levels associate with TG, abdominal
obesity, elevated glucose or low high density cholesterol. Haptoglobin levels associate with blood pressure or
elevated glucose. However, erythropoietin levels are related only with abdominal obesity. Higher serum
erythropoietin concentrations may suggest underlying adipose tissue hypoxemia in MetS.
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http://www.cardiab.com/content/11/1/116Metabolic syndrome (MetS) is a pathophysiological dis-
order with clustering of risk factors -abdominal obesity,
increased blood pressure, glucose intolerance and dysli-
pidemia - for cardiovascular disease and type 2 diabetes
[1,2]. Previous studies have reported alterations in
hematological parameters and iron metabolism: a trend
towards higher hemoglobin concentrations and serum
ferritin levels in subjects with MetS [3-6]. However, the
association between hemoglobin as well as ferritin level
and individual MetS components is still unclear.
Erythropoietin (EPO) is a glycoprotein hormone whose
production in kidneys is stimulated by hypoxia and it is
a known stimulator of erythrocyte production and
hemoglobin synthesis [7]. Recently, increasing amount
of evidence has suggested that reduced adipose tissue
oxygenation and cellular hypoxia may be an underlying
cause of adipose tissue dysfunction contributing to
metabolic changes like insulin resistance associated with
obesity and MetS [8-10]. Erythropoietin levels in sub-
jects with MetS have not been determined previously.
The aim of this study was to compare serum haptoglo-
bin, hemoglobin, ferritin, erythropoietin and transferrin
receptor levels between subjects with and without MetS
and extend these findings to include individual MetS
components.
Research design and methods
Study sample
The study population primarily consisted of 1294
middle-aged subjects from Pieksämäki, Finland, who
were born in 1942, 1947, 1952, 1957 or 1962 and invited
to a health check-up in the years 1997–1998 initially and
to a follow-up check-up in 2004. A total of 923 out of
1294 subjects participated in the initial examination in
1997–1998 and 766 of these participated in a second
health check-up in 2003–2004 when hematological la-
boratory tests were taken. These hematological labora-
tory tests were analyzed in Kuopio University laboratory
during year 2010.
The final analysis included data from these 766 sub-
jects. The study protocol was approved by the Ethics
Committee of Kuopio University Hospital and the Uni-
versity of Eastern Finland. All participants gave informed
written consent.
All subjects filled in a questionnaire about their smok-
ing habits, alcohol consumption, and physical activity.
They were also interviewed by a trained nurse. Subjects
who smoked daily were considered to be current smo-
kers. Alcohol consumption was divided into three cat-
egories: low, meaning no alcohol use; moderate (less
than two portions of alcohol per day); and high (more
than two portions per day). Physical activity was consid-
ered to be high in subjects who exercised daily at least
30 minutes in their leisure time, moderate in subjectswho exercised at least three times per week, and low
if exercising frequency was less than three times per
week [11].
Two trained nurses performed the study processing
and physical examination. Blood pressure was measured
with a mercury sphygmomanometer in a sitting position
after 15 minutes of rest. The measurement was repeated
after five minutes. The mean of the two measurements
was used in the statistical analyses. Waist circumference
was measured from the midpoint between the lateral
iliac crest and the lowest rib to an accuracy of 0.5 cm.
MetS was defined by the updated National Cholesterol
Education Program Expert Panel on Detection, Evalu-
ation and Treatment of High Blood Cholesterol in Adults
(ATP III) criteria [12]. Subjects with three or more of the
following components were classified as having MetS: (1)
increased waist circumference (≥102 cm (≥40 in) for men
and ≥88 cm (≥35 in) for women); (2) elevated fasting
total triglycerides (≥1.7 mmol/l (≥150 mg/dl) or treat-
ment for dyslipidemia); (3) low fasting serum high dens-
ity lipoprotein (HDL) cholesterol (<1.03 mmol/l
(<40 mg/dl) in men or <1.29 mmol/l (<50 mg/dl) in
women or treatment for dyslipidemia); (4) systolic blood
pressure ≥130 mmHg or diastolic blood presure
≥85 mmHg or the use of antihypertensive medication;
and (5) fasting plasma glucose ≥5.6 mmol/l (≥100 mg/dl)
or the use of antihyperglycemic medication.
Laboratory methods
Fresh serum samples were drawn after an overnight fast.
Plasma was separated by centrifugation for the deter-
mination of glucose and lipids and the samples were fro-
zen immediately and stored at - 70°C.
Samples were analyzed in Kuopio regional laboratory
during year 2010.
Plasma glucose concentration was measured by an auto-
mated colorimetric method (Peridochrom Glucose GOD-
PAP, Boehringer, Germany). Serum triglycerides were
measured from fresh serum samples by enzymatic colori-
metric methods (CHOD-PAP, GPO-PAP, Boehringer
Mannheim GmbH, Germany). Serum HDL cholesterol
was measured by the same method after precipitation of
low-density lipoprotein cholesterol and very low-density
lipoprotein cholesterol with phosphotungestic acid and
magnesium. High-sensitivity C-reactive protein (hs-CRP)
was measured with an Immulite analyzer and a DPC high-
sensitivity CRP assay (DPL, Los Angeles, CA, USA).
White blood cell and platelet count, hemoglobin and
hematocrit were measured using an automatic electronic
cell calculator. Serum EPO was analyzed using an immu-
noluminometric assay method. Serum soluble transferrin
receptor concentration was measured by a particle
enhanced immunoturbidimetric assay (Cobas c systems,
Roche Diagnostics GmbH, Mannheim, Germany). Serum
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luminescence immunoassay (Roche Diagnostics GmbH,
Mannheim, Germany).
The analytical method for plasma haptoglobin con-
centration measurements was an immunoturbidimetric
assay (Cobas c systems, Roche Diagnostics GmbH,
Mannheim, Germany, ACN 228). Serum creatinine was
measured using an enzymatic method.
Statistical analyses
The results are expressed as means and standard devia-
tions (SDs) for continuous variables and as proportions
for categorical variables. The normality of variables was
evaluated by the Shapiro-Wilk test. Statistical compari-
sons between the groups were performed using the chi-
square test, t-test, or bootstrap-type t-test as appropriate.
Bootstrap type analysis of covariance was also used to
compare the groups as measurements. In these analyses
age values, sex, smoking, physical activity and hs-CRP
values were used as covariates. For all analyses, P < 0.05
was considered significant.
Results
The study population included 425 women and 341 men
with a mean age of 52.1 ± 6.4 and 52.1 ± 6.2 years, re-
spectively. MetS was present in 52% of women and in
48% of men. Table 1 shows the clinical and lifetime fac-
tors for subjects with and without MetS. Both women
and men with MetS were significantly older than sub-
jects without. Life-style factors did not differ significantly
between subjects with or without MetS. In those with
MetS, 14% of female and 26% of male subjects were
classified as current smokers. In those without MetS, the
proportions of female and male smokers to non-smokers
were 19% and 25% respectively.
Blood pressure was the most common component of
MetS. It was present in 78% of the men and 66% of the
women. High fasting plasma glucose was also present in
a large part of the subject (75% of the men and 53% of
the men, Table 1).
Figures 1, 2, 3, 4 and 5 show standardized means for
erythropoietin, ferritin, haptoglobin, serum transferrin
receptor (sTFR) and hemoglobin in subjects with and
without MetS and in subjects with or without an indi-
vidual MetS component. All results are standardized for
age, sex, smoking, physical activity and hs-CRP. Also ad-
justment for creatinine as a marker of renal function
and for alcohol comsumption was done afterwards (data
not shown). This did not change the results. Mean
hemoglobin and mean ferritin were significantly higher
in subjects with MetS (p < 0.001). Mean erythropoietin
was significantly higher in men with MetS (p = 0.006)
and remained significantly higher in subjects with MetS
after adjusting for sex (p = 0.018). Mean haptoglobin wassignificantly higher in subjects with MetS (p = 0.018).
Mean sTFR did not differ significantly between subjects
with or without MetS.
Mean hemoglobin was significantly higher in subjects
with any of the MetS components (abdominal obesity,
blood pressure (BP), low HDL, high triglycerides (TG)
or elevated glucose). Mean ferritin was significantly
higher in subjects with abdominal obesity or low HDL
or high TG or elevated glucose component. Mean
erythropoietin was significantly higher in subjects with
abdominal obesity component but did not differ signifi-
cantly between subjects with or without other compo-
nents of MetS. Mean haptoglobin was significantly
higher in subjects with blood pressure or elevated glu-
cose component. Mean sTFR was significantly higher in
subjects with abdominal obesity component but did not
differ significantly between subjects with or without
other components of MetS.
Discussion and conclusion
To our knowledge, this is the first study to show high-
er hemoglobin, serum ferritin, haptoglobin and also
erythropoietin levels in subjects with MetS and extending
these findings to include individual MetS components.
Recently, increasing evidence has suggested that
reduced adipose tissue oxygenation and cellular hypoxia
may be an underlying cause of adipose tissue dysfunc-
tion contributing to metabolic changes associated with
obesity and MetS [8-10]. It was demonstrated that hyp-
oxia creates an insulin resistant state in human adipo-
cytes by inhibiting phosphorylation of the insulin
receptor, leading to a decrease in glucose transport [10].
Insulin resistance has been the most accepted and unify-
ing hypothesis to describe the pathophysiology of the
metabolic syndrome [1].
Also, previous studies have shown reduced adipose tis-
sue oxygenation in obese compared to normal-weight
subjects and EPO gene transcription stimulating factor
(HIF-1) over-expression in the adipose tissue of obese
subjects [8] [13]. Hypoxia is a known stimulator of
erythropoietin production as well as EPO is a stimulator
of hemoglobin synthesis [7]. EPO levels were significantly
higher in subjects with MetS as well as in subjects with
MetS abdominal obesity component in this study which
may suggest underlying adipose tissue hypoxia in MetS.
Hemoglobin levels were significantly higher in subjects
with MetS or with any of the components of MetS. This
is supported by a previous study of working-age thai
subjects that showed increased hemoglobin concentra-
tions with increasing numbers of MetS components but
only in women [14].
Further research is needed to investigate possible asso-
ciation between higher hemoglobin and EPO levels in
subjects with MetS.
Table 1 Clinical and life-style characteristics of the study population in subjects with and without the MetS
Characteristics Male p Female p
MetS present MetS not present MetS present MetS not present
N= 159 N=182 N=170 N=255
Age, years ** 53.7 (5.8) 50.7 (6.2) <0.001 54.4 (5.7) 50.5 (6.4) <0.001
Body mass index ** 29.8 (3.9) 25.2 (2.5) <0.001 30.8 (5.3) 25.1 (3.5) <0.001
Waist, cm ** 103.8 (10.7) 89.6 (7.2) <0.001 96.2 (12.4) 81.0 (8.5) <0.001
FP-gluc mmol/L ** 6.5 (1.4) 5.8 (0.8) <0.001 6.3 (1.5) 5.5 (0.4) <0.001
BP systolic, mmHg ** 143 (19) 136 (17) <0.001 144 (17) 131 (16) <0.001
BP diastolic, mmHg ** 87 (9) 82 (10) <0.001 86 (9) 79 (8) <0.001
HDL-C, mmol/L ** 1.3 (0.4) 1.6 (0.4) <0.001 1.6 (0.4) 1.8 (0.3) <0.001
Trigly, mmol/L ** 1.9 (1.5) 1.1 (0.5) <0.001 1.6 (0.8) 1.0 (0.3) <0.001
Creatinine μmol/L ** 88.5 (11.9) 85.9 (8.7) 0.02 75.3 (14.8) 73.8 (8.9) 0.17
Hemoglobin (g/L) ** 154 (9) 150 (9) <0.001* 141 (10) 136 (9) <0.001*
Ferritin (μg/L) ** 216 (165) 151 (112) <0.001* 94 (75) 61 (48) <0.001*
TFR (mg/L) ** 2.9 (2.8) 2.6 (0.6) 0.12* 2.8 (0.9) 2.7 (1.0) 0.32*
Haptoglobin (g/L) ** 1.3 (0.6) 1.1 (0.5) 0.012* 1.4 (0.6) 1.2 (0.4) <0.001*
Hs-CRP (mg/L) ** 2.4 (3.5) 1.5 (2.9) 0.058* 3.1 (3.4) 1.5 (2.3) <0.001*
Components of MetS:
Waist n (%) 102 (64) 8 (4) <0.001 134 (79) 40 (16) <0.001
FP-glucose n (%) 144 (91) 113 (62) <0.001 139 (83) 85 (33) <0.001
Blood pressure n (%) 146 (92) 119 (65) <0.001 154 (90) 126 (49) <0.001
HDL-cholesterol n (%) 90 (57) 2 (1) <0.001 101 (59) 10 (4) <0.001
Triglycerides n (%) 116 (73) 16 (9) <0.001 118 (69) 6 (2) <0.001
Life-style factors, n (%):
Current smoker 42 (26) 46 (25) 0.81 25 (14) 49 (19) 0.23
Current use of alcohol 0.038
Low (nothing) 20 (12) 26 (14) 0.055 46 (28) 46 (18)
Moderate 68 (43) 97 (54) 0.055 97 (58) 177 (70)
High 71 (45) 58 (32) 0.055 24 (14) 31 (12)
Physical activity n (%) 0.83
Low 33 (21) 56 (31) 0.11 55 (33) 80 (32)
Moderate 97 (61) 96 (53) 0.11 92 (55) 146 (57)
High 29 (18) 30 (16) 0.11 21 (12) 28 (11)
*Values are adjusted for age.
** Mean (SD).
Abbreviations: Fp-gluc, fasting plasma glucose; BP systolic, systolic blood pressure; BP diastolic, diastolic blood pressure; HDL-C, high density cholesterol; Trigly,
triglycerides; TFR, transferrin receptor; Hs-CRP, high sensitivity c-reactive protein.
Components of MetS.
1. Waist >102 cm (male) or >88 cm (female).
2. FP-glucose≥ 5.6 mmol/L.
3. Systolic blood pressure≥ 130 mmHg or diastolic ≥ 85 mmHg or antihypertensive medication.
4. HDL–cholesterol < 1.03 mmol/l (men) or < 1.29 mmol/l (women) or medication for dyslipidemia.
5. Triglycerides >1.7 mmol/l or medication for dyslipidemia.
Current use of alcohol was consireded low with no use of alcohol, moderate with use of <2 portions/day and high with use of >2 portions/day. Physical activity
was considered to be high in subjects who exercised daily at least 30 minutes in their leisure time, moderate in subjects who exercised at least three times per
week, and low if exercising frequency was less than three times per week.
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tent hypoxia, a marker for obstructive sleep apnea
(OSA), is positively associated with MetS and its
components [15]. One previous study reportedlower serum EPO concentrations after continuous
positive pressure airway treatment in patients with
OSA [16]. Also, higher serum EPO concentrations
have been reported in patients with central sleep


























p=0.015 p=0.90 p=0.16 p=0.61 p=0.73 p=0.018
Criterion not present
Criterion present
Figure 1 Eryhtropoietin mean values and individual MetS
components. All values are standardized for age, sex, hs-CRP,
smoking and physical activity. Abbreviations: BP, blood pressure;
EPO, erythropoietin; HDL, high density lipoprotein cholesterol; TFR,
transferrin receptor; TG, triglycerides. NCEP (National Cholesterol
Education Program Expert Panel on Detection, Evaluation and
Treatment of High Blood Cholesterol in Adults) criteria of MetS:
Waist >102 cm(male) or >88 cm(female); FP-glucose≥ 5.6 mmol/L;
Systolic blood pressure≥ 130 mmHg or diastolic≥ 85 mmHg or
antihypertensive medication; HDL–cholesterol < 1.03 mmol/l (men)
or < 1.29 mmol/l (women) or medication for dyslipidemia;
triglycerides >1.7 mmol/l or medication for dyslipidemia.



























p<0.001 p=0.27 p=0.020 p<0.001 p=0.002 p<0.001
Criterion not present
Criterion present
Figure 2 Ferritin mean values and individual MetS components.
All values are standardized for age, sex, hs-CRP, smoking and
physical activity. Abbreviations: BP, blood pressure; EPO,
erythropoietin; HDL, high density lipoprotein cholesterol; TFR,
transferrin receptor; TG, triglycerides. NCEP (National Cholesterol
Education Program Expert Panel on Detection, Evaluation and
Treatment of High Blood Cholesterol in Adults) criteria of MetS:
Waist >102 cm(male) or >88 cm(female); FP-glucose≥ 5.6 mmol/L;
Systolic blood pressure≥ 130 mmHg or diastolic≥ 85 mmHg or
antihypertensive medication; HDL–cholesterol < 1.03 mmol/l (men)
or < 1.29 mmol/l (women) or medication for dyslipidemia;
triglycerides >1.7 mmol/l or medication for dyslipidemia.





























p=0.19 p=0.028 p=0.087 p=0.069 p=0.025 p=0.018
Criterion not present
Criterion present
Figure 3 Haptoglobin mean values and individual MetS
components. All values are standardized for age, sex, hs-CRP,
smoking and physical activity. Abbreviations: BP, blood pressure;
EPO, erythropoietin; HDL, high density lipoprotein cholesterol; TFR,
transferrin receptor; TG, triglycerides. NCEP (National Cholesterol
Education Program Expert Panel on Detection, Evaluation and
Treatment of High Blood Cholesterol in Adults) criteria of MetS:
Waist >102 cm(male) or >88 cm(female); FP-glucose≥ 5.6 mmol/L;
Systolic blood pressure≥ 130 mmHg or diastolic≥ 85 mmHg or
antihypertensive medication; HDL–cholesterol < 1.03 mmol/l (men)
or < 1.29 mmol/l (women) or medication for dyslipidemia;
triglycerides >1.7 mmol/l or medication for dyslipidemia.


























p=0.041 p=0.098 p=0.37 p=0.52 p=0.62 p=0.17
Criterion not present
Criterion present
Figure 4 Transferrin receptor mean values and individual MetS
components. All values are standardized for age, sex, hs-CRP,
smoking and physical activity. Abbreviations: BP, blood pressure;
EPO, erythropoietin; HDL, high density lipoprotein cholesterol; TFR,
transferrin receptor; TG, triglycerides. NCEP (National Cholesterol
Education Program Expert Panel on Detection, Evaluation and
Treatment of High Blood Cholesterol in Adults) criteria of MetS:
Waist >102 cm(male) or >88 cm(female); FP-glucose≥ 5.6 mmol/L;
Systolic blood pressure≥ 130 mmHg or diastolic≥ 85 mmHg or
antihypertensive medication; HDL–cholesterol < 1.03 mmol/l (men)
or < 1.29 mmol/l (women) or medication for dyslipidemia;
triglycerides >1.7 mmol/l or medication for dyslipidemia.
Hämäläinen et al. Cardiovascular Diabetology 2012, 11:116 Page 5 of 8
http://www.cardiab.com/content/11/1/116





























p<0.001 p<0.001 p=0.002 p<0.001 p<0.001 p<0.001
Criterion not present
Criterion present
Figure 5 Hemoglobin mean values and individual MetS
components. All values are standardized for age, sex, hs-CRP,
smoking and physical activity. Abbreviations: BP, blood pressure;
EPO, erythropoietin; HDL, high density lipoprotein cholesterol; TFR,
transferrin receptor; TG, triglycerides. NCEP (National Cholesterol
Education Program Expert Panel on Detection, Evaluation and
Treatment of High Blood Cholesterol in Adults) criteria of MetS:
Waist >102 cm(male) or >88 cm(female); FP-glucose≥ 5.6 mmol/L;
Systolic blood pressure≥ 130 mmHg or diastolic≥ 85 mmHg or
antihypertensive medication; HDL–cholesterol < 1.03 mmol/l (men)
or < 1.29 mmol/l (women) or medication for dyslipidemia;
triglycerides >1.7 mmol/l or medication for dyslipidemia.
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controls [17].
Previous studies have shown associations between
serum ferritin or sTFR and increased risk of type 2 dia-
betes [18-21]. Recently, it was also shown that single nu-
cleotide polymorphism (SNP) in genes that are related
to body iron status are associated with risk of type 2 dia-
betes (T2D). SNP in gene that was related high sTFR
levels and low ferritin levels was associated with lower
risk of T2D, as well [20].
The finding that subjects with MetS had significantly
higher serum ferritin levels supports previous results
[3-6]. In addition, ferritin levels were significantly higher
in subjects with abdominal obesity or high TG or ele-
vated glucose or low high-density cholesterol MetS com-
ponent but not in subjects with blood pressure
component. Previous studies have shown that higher
serum ferritin concentrations are associated with
increased TG concentration in men and with elevated
glucose in women [3,4].
Because ferritin is an acute phase reactant, all results
were adjusted for hs-CRP to estimate the impact of in-
flammation. Ferritin levels remained significantly
higher after hs-CRP standardization suggesting that
mechanisms other than inflammation may be influen-
cing ferritin concentration in the subjects with MetS.
However, we were not able to estimate other markers
of inflammation or level of proinflammatory cytokineslike tumor necrosis factor alfa and interleukins in this
study.
Higher hs-CRP levels have also previously shown to
be associated with MetS and its separate components
as well as median hs-CRP levels to be increased with
increasing number of MetS components [21-24]. In
addition, the degree of central obesity seemed to be
the main determinant of an increased hs-CRP level [24].
In our study hs-CRP levels were significantly higher in
women with MetS and almost significantly higher in men
with MetS compared those without (Table 1).
Under hypoxia and also when erythropoiesis is stimu-
lated, human iron-regulatory hormone, hepcidin, pro-
duction is suppressed [25,26]. Theoretically, suppression
in hepcidin production could result in higher ferritin
levels seen in subjects with MetS. However, althought
reduced adipose tissue oxygenation was found in obese
subjects, hepcidin expression levels were increased, not
suppressed, in the adipose tissue of obese patients [27].
Consequently, it is unlikely that purely adipose tissue
hypoxia could cause hepcidin supression and elevated
ferritin levels.
Haptoglobin is an acute phase reactant which plasma
levels are increased during inflammation [28]. Although
the liver is the major source of haptoglobin, research has
demonstrated that it is also secreted into plasma by adi-
pose tissue [29]. Serum haptoglogin level was previously
shown to be positively associated with body fat [30]. Our
study shows higher serum haptoglobin levels in subjects
with MetS and subjects with elevated glucose or blood
pressure component even after adjusting for hs-CRP.
Serum transferrin receptor levels did not differ be-
tween subject with or without MetS, but sTFR level
was higher in subjects with abdominal obesity compo-
nent of MetS. sTFR levels are increased in iron defiency
with inadequate iron supply for erythropoiesis [31] but
also, for example secondary to use of erythropoiesis
stimulating agents such as erythropoietin [32]. Higher
sTFR levels in subjects with abdominal obesity compo-
nent of MetS suggest that despite of higher ferritin
levels, these subjects are not iron overloaded. Previous
studies have shown higher sTFR leves in obese subjects
as well as no iron accumulation in liver biopsies of
obese patients [27,33].
The strength of our study is the study population with
five age groups and no exclusion criteria. Smoking habits
between subjects with and without MetS did not differ
significantly. In addition, all results were adjusted for
smoking to exclude its influence particularly on
hemoglobin and erythropoietin levels. All results were
also hs-CRP adjusted to estimate the impact of inflam-
mation. A limitation is that hematological parameters
were measured only at the second health check-up and
cross-sectional study design does not allow identification
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women’s menopause status was not available. However,
the separate analysis was done in women for age adjus-
ment (Table 1, all data not shown). The age adjusment
did not affect the results in women. Unfortunately, we
were unable to evaluate a possibly impact of obstructive
or central sleep apnea on subjects hemoglobin or
erythropoietin levels. Also, information about nutritional
content of subjects’ diets or consumption of dietary sup-
plements like iron or antioxidants was not available.
In conclusion, Subjects with MetS have elevated
hemoglobin, ferritin, erythropoietin and haptoglobin
concentrations. Higher hemoglobin levels are related to
all components of MetS. Higher ferritin levels associate
with TG, abdominal obesity, elevated glucose or low
high-density cholesterol. Haptoglobin levels associate
with blood pressure or elevated glucose. However,
erythropoietin levels are related only with abdominal
obesity. Higher serum erythropoietin concentrations may
suggest underlying adipose tissue hypoxemia in MetS.
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